Mode
Text Size
Log in / Sign up
Phase 4 Completed N=109 Randomized Triple-blind Treatment

Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy

Source: ClinicalTrials.gov NCT02359110 ↗
Enrolled (actual)
109
Serious AEs
0.0%
Results posted
Mar 2018
Primary outcomePrimary: NRS (Numerical Rating Scale) — 3.5; 3.4; 5.4; 5.5 units on a scale — p=0.89
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The purpose of this study is to prospectively determine the influence of immediate pre-operative gabapentin administration on acute postoperative pain. The investigators hypothesize that immediate post-operative pain will be improved with pre-operative administration of gabapentin.

Outcome Measures

OutcomeResultp-value
PRIMARY
NRS (Numerical Rating Scale)
3.5; 3.4; 5.4; 5.5; 5.3; 5.8 0.89
SECONDARY
VAS (Visual Analog Scale)
37.8; 33.9; 38.7; 36.9 0.52
SECONDARY
Total Morphine Consumption
14.3; 14.7 0.88

Eligibility Criteria

Inclusion Criteria

  • The patient must be female and planning to have a laparoscopic or robotic assisted procedure for benign gynecologic indications.
  • Patients must be treated in the department of Obstetrics and Gynecology in the division of Minimally Invasive Gynecologic Surgery.
  • The patient must be in the age range of 18-80 years, in general good health and able to comply with study procedures.

Exclusion Criteria

  • Male patients will be excluded from this study.
  • Patients under 18 years old will be excluded from this study.
  • Pregnant patients. All patients will have a routine pre-operative urine HCG to exclude pregnancy.
  • Patients having abdominal, vaginal or hysteroscopic procedures
  • Allergy to gabapentin
  • Chronic use of gabapentin (greater than 6 months)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02359110). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search